PTC Therapeutics Announced An Agreement With Royalty Pharma To Monetize Up To $1.5B Of The Evrysdi Royalty Stream. Under The Agreement, Royalty Pharma Acquires Additional Royalties On Evrysdi For $1B Upfront
Author: Benzinga Newsdesk | October 19, 2023 08:07am
The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. PTC maintains all economics associated with up to $250 million in remaining commercial sales milestones associated with Evrysdi global net sales.
Posted In: PTCT RPRX